4085 results about "Virology" patented technology

The invention discloses a virulent bacteriophage vBValSR36H with a host being vibrio alginolyticus and application of the virulent bacteriophage vBValSR36H, and relates to the technical field of microbial control. The invention provides a bacteriophage capable of efficiently cracking Vibrio alginolyticus ATCC 17749T, the bacteriophage is named as vBValSR36H, the preservation number is 66248-B1, and the preservation address is Institute of Microbiology, Academy of Sciences in Guangdong Province. The vibrio alginolyticus bacteriophage vBValSR36H provided by the invention has good environmental stability and certain bactericidal activity, and has a relatively wide environmental adaptation range and relatively long survival time. The bacteriophage vBValSR36H provided by the invention can specifically and effectively kill, prevent and control related vibrio diseases, meanwhile, virulence factor genes and drug-resistant genes are not detected in the bacteriophage, and the bacteriophage vBValSR36H has the advantages of no toxic or side effect, high safety, environmental friendliness and wide application prospect. Therefore, the vibrio alginolyticus bacteriophage vBValSR36H can be completely applied to killing and / or preventing vibrio alginolyticus for non-disease diagnosis and treatment purposes.

The invention discloses a broad-spectrum lytic bacteriophage for preventing and controlling various vibrio infections in an aquaculture environment. The invention relates to V.alginolyticus phage vBValM-R37J, which is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on August 6, 2025, the address is No.100 Courtyard, Xianlie Middle Road, Xianlie District, Guangzhou City, Guangdong Province, the postcode is 510070, and the preservation number is GDMCC NO.66813-B1. The invention further discloses a method for preparing the V.alginolyticus phage vBValM-R37J strain. The bacteriophage R37J is a candidate therapeutic bacteriophage with wide host spectrum, high splitting efficiency, gene safety and environmental stability, and has the potential of being popularized and applied in aquaculture as a novel biological tool for accurately preventing and controlling various vibrio infections. A new biological resource is provided for accurate prevention and control of aquatic pathogenic bacteria, and a theoretical basis and a technical support are provided for popularization and application of a phage therapy in an actual culture system.

The present disclosure provides an antibody or antigen-binding fragment thereof that specifically binds to human cMET. The disclosure also provides polynucleotides encoding the antibodies or antigen binding fragments thereof, vectors comprising the polynucleotides, host cells comprising the vectors, methods of generating the antibodies, and compositions comprising the antibodies.

The invention discloses a kit and a method for HLA cross reaction group and HPA genotyping. The system for HLA cross reaction group and HPA genotyping detection is obtained through respective combination design of two different primers on the basis of common specific SNP loci, and rapid, simple, low-cost and high-throughput HLA epitope and HPA genotyping detection can be realized, so that platelet infusion ineffectiveness and immune platelet infusion ineffectiveness are more effectively prevented.

The invention discloses an application of CD4 + CD8 + double-positive T cells in improvement of poor immune reconstitution of HIV (human immunodeficiency virus) infected patients, and relates to the technical field of biological pharmacy, in particular to the application of preparation of the CD4 + CD8 + double-positive T cells in the poor immune reconstitution of the HIV infected patients. The number of peripheral blood CD4 + T cells of HIV infected patients is increased, the immune system of the patients is improved, and the probability of possible opportunity infection and other related diseases of the patients is reduced, so that the morbidity and mortality of the patients are reduced.

The invention relates to the technical field of biomedicine, in particular to a primer probe combination for broad-spectrum screening of common respiratory pathogens and application of the primer probe combination. Through screening and optimization, the respiratory pathogen nucleic acid detection primer probe combination for broad-spectrum screening of common acute respiratory infection and community-acquired pneumonia is obtained; the primer probe combination covers 18 respiratory tract pathogens, has the advantages of high accuracy, good specificity, strong anti-interference capability, good inclusiveness, high sensitivity, hyperjoint detection and the like, can realize parallel detection of 20 targets in cooperation with totally-closed single-tube PCR amplification, greatly improves early diagnosis of respiratory tract diseases with complex pathogen structures, and has wide application prospects. The method has very important significance on prevention, control and treatment of infectious diseases.

The invention discloses an anti-human inflammatory factor interleukin 6 monoclonal antibody and an application thereof. When the monoclonal antibody is prepared, an adopted immunogen is a human inflammatory factor interleukin 6 antigen, and an amino acid sequence of the human inflammatory factor interleukin 6 antigen comprises a sequence as shown in SEQ ID NO: 1. A group of monoclonal antibodies specifically combined with antigens is constructed based on the IL-6 antigens. The IL-6 monoclonal antibody has strong binding capacity with an IL-6 antigen in a clinical sample, has no cross reaction with other proteins, has good specificity and affinity compared with a commercial antigen, can be effectively applied to ELISA and a dry-type immunofluorescence method, has good detection linearity, precision, stability and accuracy, and can be widely applied to the field of immunoassay. The antibody can be combined with the antigen to serve as a detection reagent raw material combination, and has clinical detection advantages.

The invention relates to a PLpro protease small-molecule inhibitor for treating or preventing coronavirus infection and application of the PLpro protease small-molecule inhibitor. Specifically, the invention relates to a compound shown as a formula (I) or an isotope labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer or an isomer mixture thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, and the use thereof in the preparation of a medicament for treating or preventing coronavirus infection or diseases or symptoms caused by coronavirus.

The invention discloses preparation and application of an anti-staphylococcus aureus IsdB antibody. The antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 8; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 16. The invention also provides nucleic acid for coding the antibody, a vector containing the nucleic acid and a cell containing the vector. In addition, experiments prove that the antibody can inhibit systemic infection of MRSA and resist invasion of MRSA to pneumonia, and has a good clinical application prospect.

The invention provides an RNA polymerase variant and application thereof, and relates to the technical field of biology. Wild type T7 RNA polymerase is modified to obtain the T7 RNA polymerase variant, the enzyme specific activity of the T7 RNA polymerase variant is remarkably improved compared with that of the wild type T7 RNA polymerase, the addition amount of the polymerase in the in-vitro transcription reaction process can be reduced, and the cost is saved; in addition, the mutant also effectively reduces the generation of incomplete fragment impurities, and the mRNA integrity is significantly improved to 99%. The invention further provides a method for preparing RNA through in-vitro transcription.

The present disclosure provides an antibody or antigen-binding fragment thereof that specifically binds to human cMET. The disclosure also provides polynucleotides encoding the antibodies or antigen binding fragments thereof, vectors comprising the polynucleotides, host cells comprising the vectors, methods of generating the antibodies, and compositions comprising the antibodies.

The application belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting canine parainfluenza virus NP protein and application thereof. The combination is composed of monoclonal antibodies 5H10 and 1H7, 5H10 is used as a coating antibody, and 1H7 is used for colloidal gold labeling, so that efficient and specific sandwich detection of CPIV / NP antigen can be realized. The variable region CDR sequences of the heavy chains and light chains of the two antibodies are clear (SEQ ID NO. 1-12). The application also provides a rapid detection test strip based on the antibody combination, which can be used for on-site screening, early diagnosis and epidemiological monitoring of canine parainfluenza virus, solves the problem that existing detection technologies lack high-specificity recognition tools, and has a good application prospect.

The invention discloses an application of cryptotanshinone in preparation of an anti-mycobacterium tuberculosis drug, and relates to the technical field of bioengineering. The molecular formula of the valerianin disclosed by the invention is C19H20O3. The mycobacterium tuberculosis is a mycobacterium tuberculosis H37Rv strain. Cryptotanshinone is disclosed as a natural-source compound for the first time, has the dual advantages of high efficiency and low toxicity, has an obvious effect of resisting mycobacterium tuberculosis, provides a brand new candidate drug scheme with development potential for solving the difficulty of tuberculosis treatment, and has great scientific value and application prospect.

The invention provides a group of monoclonal antibody pairs targeting adenovirus DBP protein, the monoclonal antibody pairs comprise a capture antibody and a detection antibody, each of the two antibodies comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, the light chain variable region comprises light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, and the capture antibody and the detection antibody are used for capturing and detecting the adenovirus DBP protein. Wherein the capture antibody is a monoclonal antibody 19E3; and the detection antibody is selected from a monoclonal antibody 96 to 10D8, a monoclonal antibody 95 to 2B7, a monoclonal antibody 96 to 2C10, a monoclonal antibody 96 to 8E10, a monoclonal antibody 96 to 13D5 or a monoclonal antibody 96 to 2B10. The monoclonal antibody pair disclosed by the invention can be used for efficiently detecting various types of HAdV DBP.

The invention discloses a multi-subtype influenza A virus nucleic acid detection kit and a detection method, and relates to the technical field of medical detection.The kit comprises a group of reverse transcription RT-RPA amplification primer pairs used for amplifying influenza A virus M gene target sequences, the reverse transcription RT-RPA amplification primer pairs are designed for specific areas of subtypes H1N1, H2N2, H3N2, H5N1 and H7N9, and the reverse transcription RT-RPA amplification primer pairs are designed for specific areas of subtypes H1N1, H2N2, H3N2, H5N1 and H7N9; the crRNA library comprises a plurality of crRNA molecules which are respectively complementary with different conserved regions in the M gene target sequence and is used for guiding Cas12a protein to carry out specific recognition; a Cas12a protein reagent; the reporter molecule can be subjected to non-specific cleavage by the Cas12a protein; the enzyme preparation, the buffer solution and the nucleotide substrate are required by RT-RPA reaction. The invention aims to realize synchronous, rapid, high-sensitivity and high-specificity detection of various subtype influenza A viruses.

The invention discloses a carbapenem drug resistance gene detection reagent or kit, the detection reagent comprises a PCR detection liquid, the PCR detection liquid comprises upstream and downstream primer sequences and probe sequences of target genes, and the target genes are KPC, OXA-23, NDM, VIM and IMP. The invention also discloses application of the reagent or the kit. The reagent / kit provided by the invention has simple components, only comprises a PCR detection liquid and negative and positive quality control, can obtain detection results of five major carbapenem drug resistance genes, namely KPC, OXA-23, NDM, VIM and IMP, within about 50 minutes only once, and is simple and convenient to operate, low in detection cost, short in detection time and high in sensitivity. In addition, the lowest detectable concentration of detection of carbapenem drug resistance genes KPC, OXA-23, NDM, VIM and IMP is 10 copy / mL, and the sensitivity is high.

The invention discloses a respiratory infectious disease multi-pathogen nucleic acid detection kit based on a fluorescent PCR detection technology and application of the respiratory infectious disease multi-pathogen nucleic acid detection kit. The invention provides two detection kits aiming at 20 and 6 respiratory tract detection, the two kits can specifically detect respiratory tract pathogens, the detection sensitivity is high, the whole detection system is short in time consumption and simple and convenient in use process, and detection results of 20 pathogenic microorganisms can be reported within 40 min at the shortest; the whole set of detection kit and the detection method are high in sensitivity and good in specificity; the normal-temperature storage and transportation of the reagent can be realized.

The invention provides sgRNA for targeting and guiding nuclease to efficiently cut an HLA-DRA gene, a method for modifying a CAR-T cell by using the sgRNA, and a related gene editing system, reagent and kit. According to the CAR-T cell, the immunogenicity is greatly reduced, the risk of graft versus host disease and immunological rejection can be effectively reduced, and meanwhile the killing capacity of tumor cells of the CAR-T cell is not affected.

The invention belongs to the technical field of biological detection, and particularly discloses a targeted sequencing primer group and a kit for detecting common pathogens of children and drug-resistant genes thereof. The primer group comprises 145 primer pairs of common children pathogen primer groups and 67 primer pairs of drug-resistant gene primer groups of the common children pathogen primer groups. According to the kit provided by the invention, nucleic acid in a clinical sample is directly extracted, 212 pairs of specific primers are adopted to realize multi-targeted amplification of a pathogen target area, a high-throughput sequencing platform is adopted to accurately identify pathogens and drug-resistant mutant genes thereof, 72 common children pathogens and drug-resistant genes thereof can be detected at the same time, and the kit has a wide application prospect. More accurate diagnosis information is provided for clinic, a key technical support is provided for early-stage accurate treatment of children infectious diseases, and the technical problems that in the prior art, in children pathogen detection, the detection speed is low, the number of missed detection is large, and the drug-resistant blind area is large are solved.

The invention belongs to the field of biomedical detection, and particularly relates to a protein chip, a detection kit based on a polypeptide coding microarray chip and application of the detection kit. According to the protein chip provided by the invention, an antibody and a bispecific antibody of corresponding indexes can be added into a treating fluid according to detection requirements, the antibody and the bispecific antibody are combined with the chip in a manner of polypeptide specific recognition after being subjected to antigen specific recognition respectively, and joint detection of different antigen combinations and detection of a single index are carried out. By utilizing the polypeptide sample application chip and the antigen and antibody combined bispecific antibody provided by the invention, the universality of the chip in use, the high efficiency of detection and the low cost can be remarkably improved.

The invention provides sgRNA for targeting and guiding nuclease to efficiently cut a B2M gene, a method for modifying cells by using the sgRNA, and a related gene editing system, reagent and kit. The cells produced by the invention greatly reduce the immunogenicity, can effectively reduce the risk of graft versus host disease and immunological rejection, and does not affect the killing ability of the cells to tumor cells.

The invention provides a CLDN6 single domain antibody and a humanization method thereof. The CLDN6 single-domain antibody provided by the invention has targeted specificity to CLDN6, only recognizes the CLDN6 and does not recognize CLDN3, CLDN4 and CLDN9 of the same family, or the recognition modes are obviously different. The CLDN6 single-domain antibody 1H07 with targeting specificity provided by the invention can be used for constructing a chimeric antigen receptor (CAR) and a bivalent antibody (bispecific antibody). The CAR constructed based on the antibody sequence can be transduced into a T cell to create a CAR-T cell specifically targeting CLDN6, and the CAR-T cell can be used for treating solid tumors such as ovarian cancer.

The invention belongs to the field of antibody development, and discloses a screening method and application of a human-mouse protein high homologous target antibody based on a fully humanized antibody mouse. Aiming at the problem of weak antibody response caused by immune tolerance of human-mouse high homologous targets (protein homology is greater than or equal to 95%), the following scheme is provided: in embryonic stem cells (ES cells) of HUGO-Mabfully humanized antibody transgenic mice, a mouse target gene (such as ACVR2A) is knocked out through a Turbo Knockout technology, and homozygous knockout ES clones are screened; carrying out microinjection on the clones to the whitened B6 mouse blastocyst, and transplanting a pregnant mouse to obtain a Founder mouse; the Founder mouse is subjected to target antigen immunization for more than or equal to 4 times (the Freund's complete adjuvant is used for the first time), and the titer of the serum antibody is detected. According to the invention, 100% homozygous knockout chimeric efficiency is realized in the Founder stage, the mouse construction period is shortened from traditional 8-10 months to 3-4 months, and the diversity and affinity of the antibody are significantly improved (titer reaches 1: 729,000). The obtained antibody can be used for preparing medicines for treating tumors or autoimmune diseases.

The invention discloses a porcine delta coronavirus monoclonal antibody and application thereof in preparation of an antigen detection test strip. The detection test strip comprises a polyvinyl chloride bottom plate on the lowest layer, and a sample pad, a conjugate pad, a nitrocellulose membrane and a water absorption pad are sequentially laid on the polyvinyl chloride bottom plate in the flowing direction; the sample pad is partially overlapped on the combination pad, and the combination pad and the water absorption pad are respectively overlapped on two sides of the nitrocellulose membrane; a detection line and a quality control line are arranged on the nitrocellulose membrane along the flowing direction; an antibody marked by red latex microspheres is sprayed on the combination pad, a coated antibody is sprayed on the detection line, and coated commercial goat anti-mouse IgG is sprayed on the quality control line. The test strip adopts a double-antibody sandwich method for detection, and has the advantages of high detection speed, high sensitivity, strong specificity and the like. The detection result is visual, clear and easy to interpret; the detection process does not need any instrument and equipment, operators do not need professional training, operation is easy and convenient, and the method is particularly suitable for on-site rapid diagnosis.

The invention discloses a klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 and application thereof, and relates to the technical field of biology. The klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 is preserved in Guangdong Microbial Culture Collection Center on October 14, 2024, the preservation address is the 5th floor of the building 59, No.100 Courtyard, Xianlie Middle Road, Guangzhou, and the preservation number is GDMCC No: 65268-B1. The bacteriophage keeps stable titer in a wide pH range (4-10) and a temperature interval (4-50 DEG C), and the highest titer can reach more than 109 pfu / mL. The bacteriophage can efficiently split klebsiella pneumoniae. The invention provides powerful technical support for developing novel antibacterial drugs and treatment schemes for klebsiella pneumoniae, and shows wide application prospect and potential clinical value.

The present disclosure provides an antibody or antigen-binding fragment thereof that specifically binds to human cMET. The disclosure also provides polynucleotides encoding the antibodies or antigen binding fragments thereof, vectors comprising the polynucleotides, host cells comprising the vectors, methods of generating the antibodies, and compositions comprising the antibodies.

As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and / or agonistic activity.

This invention discloses a camel-derived CRP single-domain antibody, its preparation method, and its applications, relating to the biomedical field. The method involves enriching CRP antigen in alpaca leukocytes immunized with the antigen, followed by single-cell screening and sequencing. Through sequencing structural analysis, a recombinant plasmid of the camel-derived CRP antibody is constructed. This plasmid is cloned and transformed into eukaryotic cells to express related antibodies. Monoclonal antibodies with human CRP resistance are screened for expression. The VHH domain of the monoclonal antibody is cloned and expressed, and paired screening yields CRP-VHH monoclonal antibodies with antibody activity. This antibody can be used in ELISA kits, chemiluminescence kits, and latex kits, possessing the same functionality as existing kits. Furthermore, this antibody also has applications in the preparation of antitumor drugs.

The invention provides an application of a lactobacillus paracasei IOB413 metagen in prevention of helicobacter pylori infection, and relates to the technical field of microorganisms. The lactobacillus paracasei IOB413 metaplasm can competitively occupy gastric epithelial cell adhesion sites to directly block the initial colonization of helicobacter pylori, so that infection preposed interception is realized, and the lactobacillus paracasei IOB413 metaplasm is suitable for early prevention of high-incidence people. The compound has dual mechanisms of site blocking and urease inhibition, and can cooperate with antibiotics to improve the eradication rate and reduce the drug resistance. Animal experiments show that the traditional Chinese medicine composition can reduce gastric mucosa proinflammatory factors in a dose-dependent manner, improve the activity of antioxidant enzymes, reduce lipid peroxidation products, relieve mucosa lesion, promote repair and reduce the risk of complications; moreover, gastrointestinal hormone disorder can be reversed, the digestive function is maintained, and related discomfort is relieved.

The invention discloses dsRNA of a targeted BdSpt7 gene, a biocontrol agent and application of the dsRNA. The sequence of the dsRNA of the targeted BdSpt7 gene is as shown in SEQ ID No.2. The invention further discloses a preparation method of the biocontrol agent of the targeted BdSpt7 gene. The active ingredient of the biocontrol agent is the dsRNA of the target BdSpt7 gene. The invention also provides an application of the botryosphaeria dothidea BdSpt7 gene in prevention and treatment of apple botryosphaeria dothidea, and a nucleotide sequence of the botryosphaeria dothidea BdSpt7 gene is shown as SEQ ID No.1. The invention also provides an African trichoderma harzianum engineering strain for expressing dsRNA, the African trichoderma harzianum engineering strain is integrated with a dsRNA expression box for interfering gene expression of a target gene BdSpt7, the dsRNA expression box is shown as SEQ ID No.1, and the African trichoderma harzianum is an African trichoderma harzianum with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No. 41709. The dsRNA targeting the BdSpt7 gene can significantly reduce the pathogenicity of the physalospora piricola through interference, and the African trichoderma harzianum engineering strain can colonize on the plant surface and continuously express the dsRNA so as to play a role in preventing and treating the physalospora piricola, and is green and environment-friendly.